USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
levafoxolaner: insecticide for killing fleas and ticks in dogs
cirotregcel: treatment of auto-immune disorders, specifically type 1 Diabetes
dilancorcel: reconstitution of the hematopoietic system to fight chemotherapy induced neutropenia
edatristat: treatment of pulmonary arterial hypertension
ledacorcel: reconstitution of the hematopoietic system to fight chemotherapy induced neutropenia
rodatristat: treatment of pulmonary arterial hypertension
temastermin: locally administered agent to increase muscle mass and strength in specific muscles, for the treatment of focal myopathies
mipretinib: treatment of cancer
ripretinib: treatment of cancer
turzepatide: treatment of type 2 diabetes
vanotagrin mesylate: treatment of cognition disorders; treatment of Alzheimer’s disease